Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 73,044	$ 72,540	$ 140,210	$ 145,229
Research and development related success payments and contingent consideration	26,679	(17,928)	26,799	(73,366)
General and administrative	16,566	18,292	33,332	32,726
Total operating expenses	116,289	72,904	200,341	104,589
Loss from operations	(116,289)	(72,904)	(200,341)	(104,589)
Interest income, net	2,374	637	4,350	976
Other expense, net	(84)	(198)	(131)	(300)
Net loss	$ (113,999)	$ (72,465)	$ (196,122)	$ (103,913)
Net income (loss) per common share - basic	$ (0.59)	$ (0.39)	$ (1.02)	$ (0.56)
Net income (loss) per common share - diluted	$ (0.59)	$ (0.39)	$ (1.02)	$ (0.56)
Weighted-average number of common shares - basic	192,540	187,626	191,888	186,801
Weighted-average number of common shares - diluted	192,540	187,626	191,888	186,801